Munich Re has spent the past five months steadily shrinking its share count, but the German reinsurer’s capital return program is now running against a noticeably less friendly pricing environment. The stock changed hands at EUR 508.80 on Tuesday, down 0.5% on the day, as investors weighed a survey suggesting the hard market that powered the sector’s recent profits may be loosening.
The mood across European reinsurance has turned cautious. Jefferies cut its price target on Munich Re to EUR 550 on September 28 while keeping a “Hold” rating, and the shares came under visible pressure in the aftermath. The more consequential signal, though, came from a Moody’s poll of primary insurers: 86% of those surveyed expect further price declines in property-casualty reinsurance by 2027.
That finding rippled well beyond Munich Re. European peers Hannover Re and Swiss Re also softened as the survey circulated, underscoring how much of the sector’s recent earnings power has rested on consecutive years of rate increases. If primary carriers succeed in pushing through meaningful discounts at the upcoming renewal rounds, the margin cushion in reinsurers’ core business will thin considerably.
A North American Care Block Takes Shape
Against that softening backdrop, Munich Re’s operational news has been decidedly expansionary. Its subsidiary Munich American Reassurance Company finalized an agreement with Manulife Financial Corporation covering biometric risks tied to a portfolio of long-term care policies. The block carries actuarial reserves of CAD 3.2 billion, with the US life reinsurance arm assuming 80% of the risk while Manulife continues to administer the contracts.
The deal cuts both ways for investors trying to gauge Munich Re’s trajectory. Long-term care policies are widely regarded as tricky to model, since life expectancy and care costs shift over decades. Should the assumptions underpinning the covered contracts understate future claims, the 80% quota could turn into a drag, and unexpected reserve strengthening would eat into future payouts. Get the actuarial steering right, however, and the CAD 3.2 billion block delivers dependable premium income while showcasing Munich Re’s balance sheet strength in global life and health specialty risk.
Should investors sell immediately? Or is it worth buying Münchener Rück?
Amundi Crosses the Three Percent Line
Institutional money has been moving in the opposite direction from the pricing pessimists. French asset manager Amundi lifted its stake in the DAX-listed group, crossing a reporting threshold with a voting rights share of 3.013% as of September 28, up from 2.999% previously. The disclosure points to confidence in the business model at a time when the shares sit well below their 52-week high of EUR 575.40 and have posted a year-to-date loss of 9.1%.
Munich Re’s own buying has reinforced that signal. The company repurchased another 102,937 of its own shares between September 24 and October 2, bringing the total acquired since the current program began on May 14 to 2,943,260. The steady retirement of stock, combined with Amundi’s accumulation, is gradually tightening the supply of freely tradable shares — a mechanism that can help the paper chip away at this year’s decline.
What November Will Reveal
Attention now shifts to two scheduled appearances that should sharpen the picture. On October 15, Munich Re hosts a virtual media breakfast alongside the industry gathering in Baden-Baden, where the direction of the coming treaty renewals typically takes center stage. Hard numbers follow on November 12 with the quarterly statement for the period ending September 30.
That report will show how the new North American business and the claims experience of recent months actually land in the financials. Until then, the buyback provides a floor of sorts — but a soft market or a heavy catastrophe quarter could neutralize its effect quickly. Should confidence in underwriting discipline on large international treaties waver, the stock’s footing would look considerably less secure.
Ad
Münchener Rück Stock: Buy or Sell?! New Münchener Rück Analysis from October 6 delivers the answer:
The latest Münchener Rück figures speak for themselves: Urgent action needed for Münchener Rück investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 6.
Münchener Rück: Buy or sell? Read more here...
